


Donor 2773

Genetic Testing Summary



Last Updated: 06/24/19

Donor Reported Ancestry: German, Irish, Scottish, Polish

Jewish Ancestry: No

Genetic Test*	Bogult	Comments/Donor's Residual Risk**
Genetic rest	Result	Comments/ Donor's Residual Risk

Chromosome analysis (karyotype)	Normal male karyotype	No evidence of clinically significant chromosome abnormalities	
Hemoglobin evaluation	Normal hemoglobin fractionation and MCV/MCH results	Reduced risk to be a carrier for sickle cell anemia, beta thalassemia, alpha thalassemia trait (aa/ and a-/a-) and other hemoglobinopathies	
Cystic Fibrosis (CF) carrier screening	Negative by genotyping of 99 mutations.	1/310	
Spinal Muscular Atrophy (SMA) carrier screening	Negative for deletions of exon 7 in the SMN1 gene	1/700	
Tay Sachs Disease by enzyme analysis	Negative by Hexosaminidase enzyme analysis		
Sickle Cell Disease	Negative for 28 mutations tested in the HBB gene	<1/500	
Beta Thalassemia	Negative for 27 mutations tested in the HBB gene	1/1500	
Alpha-1-Antitrypsin Deficiency- see attached	Carrier: Z mutation in the SERPINA1 gene	Partner testing is indicated before use	
Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency- see attached	Carrier: Non-Classic variant in the CYP21A2 gene	Partner testing is indicated before use	

*No single test can screen for all genetic disorders. A negative screening result significantly reduces, but cannot eliminate, the risk for these conditions in a pregnancy.**Donor residual risk is the chance the donor is still a carrier after testing negative.



Results Recipient Fair ryobank - Fairfax

Name: DONOR 2773 DOB: Ethnicity: Northern European Sample Type: EDTA Blood Date of Collection: 09/16/2011 Barcode: Indication: Egg or Sperm Donor



Report Date: 09/27/2011

Counsyl Test Results (Egg or Sperm Donor)

The Counsyl test uses targeted DNA mutation analysis to simultaneously determine the carrier status of an individual for a number of Mendelian diseases. This report indicates which mutations, if any, were detected for each mutation panel. Because only select mutations are tested, the percentage of carriers detected varies by ethnicity. A negative test result does not eliminate the possibility that the individual is a carrier. Interpretation is given as an estimate of the risk of conceiving a child affected with a disease, which is based on reported ethnicity, the test results, and an assumption of no family history.

Male



DONOR 2773

DONOR 2773's DNA test shows that he is not a carrier of any disease-causing mutation tested.



The reproductive risk presented is based on a hypothetical pairing with a partner of the same ethnic group.

Reproductive Risk Summary

No increased reproductive risks to highlight. Please refer to the following pages for detailed information about the results.

Clinical notes:

 Individuals of African, Southeast Asian, and Mediterranean ancestry are at increased risk for being carriers for hemoglobinopathies and may also benefit from carrier testing by CBC and hemoglobin electrophoresis or HPLC. ACOG Practice Bulletin No. 78. Obstet Gynecol 2007;109:229-37.

To schedule a free appointment to speak with a genetic counselor about your results, please visit www.counsyl.com/appointment.

* Limitations: In an unknown number of cases, nearby genetic variants may interfere with mutation detection. Other possible sources of diagnostic error include sample mix-up, trace contamination, and technical errors. The reproductive risk summary is provided as an aid to genetic counseling. Inaccurate reporting of ethnicity may cause errors in risk calculation.

This test was developed and its performance characteristics determined by Counsyl, Inc. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. These results are adjunctive to the ordering physician's workup. CLIA Number: #05D1102604. Lab Directors: Jessica Jacobson, MD, William K. Seltzer, PhD, FACMG.



Male Name: DONOR 2773 DOB Female Not tested

Risk before testing:

1 in 4.800

Full Results

 $\cdot \mathbf{A}$

 \mathbf{v}

 \mathbf{V}

Below are the full test results for all diseases on the panel. Noted are the specific genetic mutations for which the patient tested positive or negative. If there was insufficient data to determine the genotype for any variant, this will be noted as "no call." Also listed in this section is the patient's post-test risk of being a carrier of each disease as well as the odds that his future children could inherit each disease.

V Beta Thalassemia	Reproductive risk: Less than 1 in 1,000,000	Risk before testing: 1 in 250,000	क्षित्रप्रस्टकां संहरे
DONOR 2773: No mutations detected. This does not rule out t assuming a negative family history, is 1 in 1,500. 83% detectio	he possibility of being a carrier of untested min nate.	utations. The post-test risk of b	eing a carrier,
Gene: HBB. Variants (27): K17X, Q39X, Phe41fs, Ser9fs, IVS-II-654, IVS-II-7 IVS-II-849(A>G), Giy24 T>A, -87C>G, Hb C, W15X, Gly16fs, Glu6fs, Hb E, Hb	45, IVS-II-850, IVS-I-6, IVS-I-110, IVS-I-5, IVS-I-1(G>A), ΣΡ-Ρ⊔nja5, Hb O-Arab.	, -88C>ĭ, -28A>G, -29A>G, Lys8fs, Ph	e71fs, IVS-II-849(A>C).

				No. Residence of the contract
\checkmark	Cystic Fibrosis	Reproductive risk:	Risk before testing:	
		1 in 34,000	1 in 3,000	Noticed risk

DONOR 2773: No mutations detected. This does not rule out the possibility of being a carrier of untested mutations. The post-test risk of being a carrier, assuming a negative family history, is 1 in 310. 91% detection rate.

Gene: CFTR. Variants (99): G85E, R117H, R334W, R347P, A455E, G542X, G551D, R553X, R560T, R1162X, W1282X, N1303K, F508del, I507del, 2184delA, 3659delC, 621+1G>T, 711+1G>T, 1717-1G>A, 1898+1G>A, 2789+5G>A, 3120+1G>A, 3849+10kbC>T, E60X, R75X, E92X, V122X, G178R, R347H, Q493X, V520F, S549N, P574H, M1101K, D1152H, 2143delT, 349delT, 349delT, 387delA, 3905insT, 1812-1G>A, 3272-26A>G, 2183AA>G, S549R(A>C), R117C, L206W, G330X, T338L, R352Q, S364P, G480C, C524X, S549R(T>G), Q552X, A559T, G622D, R709X, K710X, R764X, Q890X, R1066C, W1089X, V1092X, R1158X, S1196X, W1204X(c.3611G>A), Q1238X, S1251N, S1256X, 3199del6, 574delA, 663delT, 935delA, 197delTA, 1849del84, 2043delG, 2055del9>A, 2108delA, 3171delC, 3667del4, 3791delC, 1288insTA, 2184insA, 2307insA, 2869insG, 296+12T>C, 405+1G>A, 405+3A>C, 406-1G>A, 711+5G>A, 712-1G>T, 1898+1G>T, 1898+5G>T, 3120G>A, 457TAT>G, 3849+4A>G, Q359K/T360K.

1				
/	Sickle Cell Disease	Reproductive risk:	Risk before testing:	
		Less than 1 in 1,000,000	less than 1 in 1,000,000	
	DONOR 2773: No mutations detected. This does not rule out the possibility of t assuming a negative family history, is < 1 in 500. 70% detection rate.	eing a carrier of untested mutatic	ons. The post-test risk of being a carrier,	
	Gene: HBB. Variants (28): Hb S, K17X, Q39X, Phe41fs, Ser9fs, IVS-II-654, IVS-II-745, IVS-II-850, II-849(A>C), IVS-II-849(A>C), Gly24 T>A, -87C>C, Hb C, W15X, Gly16fs, Glu6fs, Hb E, Hb D-Punj	IVS-I-6, IVS-I-110, IVS-I-5, IVS-I-1(G>A), ab, Hb O-Arab.	, -88C>T, -28A>G, -29A>G, Lys8fs, Phe71fs, IVS-	

Reproductive risk:

1 in 97,000

Spinal Muscular Atrophy

DONOR 2773: No mutations detected. This does not rule out the possibility of being a carrier of untested mutations. The post-test risk of being a carrier, assuming a negative family history, is 1 in 700. 95% detection rate. Gene: SMN1. Variants (1): Exon 7 detection.

This test was developed and its performance characteristics determined by Counsyl, Inc. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. These results are adjunctive to the ordering physician's workup. CLIA Number: #05D1102604. Lab Directors: Jessica Jacobson, MD, William K. Seltzer, PhD, FACMG.

Reduced Hak



Carrier Map™

Ordering Practice:	Donor 2773	Partner Not Tested
Practice Code: Fairfax Cryobank	DOB: Gender: Male	
	Ethnicity: European	
	Procedure ID: 40651	
Physician: Report Generated: 2016-01-20	Kit Barcode:	
Report Generated: 2010-01-20	Method: Genotyping Specimen: Sperm, #42574	
	Specimen Collection: 2016-01-12	
	Specimen Received: 2016-01-13	
	Specimen Analyzed: 2016-01-20	
SUMMARY OF RESULTS		MUTATION(S) IDENTIFIED
Disease	Donor 2773	Partner Not Tested
Alpha-1-Antitrypsin Deficiency	Carrier (1 abnormal copy)	
Moderate Impact	Mutation: c.G1096A (p.E366K)	
·	Gene: SERPINA1	
	Method: Genotyping	

All other mutations analyzed were not detected, reducing but not eliminating your chance to be a carrier for the associated genetic diseases. A list of all the diseases and mutations you were screened for is included later in this report. The test does not screen for every possible genetic disease.

For disease information, please visit www.recombine.com/diseases. To speak with a Genetic Counselor, call 855.OUR.GENES.

Reproductive risk detected. Consider partner testing.

o^r Male

Panel: Custom Panel, Diseases Tested: 1, Mutations Tested: 4, Genes Tested: 1, Null Calls: 0

Assay performed by Reprogenetics CLIA ID: 31 D1054821 3 Regent Street, Livingston, NJ 07039 Lab Technician Bo Chu

Recombine CLIA # 31D2100763 Reviewed by Pere Colls, PhD, HCLD, Lab Director

This test was developed and its performance determined by Recombine Inc. and it has not been cleared or approved by the U.S. Food and Drug Administration.

💥 Recombine

Alpha-1-Antitrypsin Deficiency

Alpha-1 Antitrypsin Deficiency is an inherited condition that can cause lung and liver disease. This disease is caused by mutations in the SERPINA1 gene, which is normally responsible for producing alpha-1 antitrypsin protein. This protein controls the activity of the neutrophil elastase enzyme, which is released by white blood cells to fight infection. Without adequate alpha-1 antitrypsin, neutrophil elastase can damage healthy lung tissue. Abnormally formed alpha-1 antitrypsin can also accumulate in the liver, where it is produced, and damage liver tissue. Affected individuals develop lung disease between the ages of 20 and 50. The most common symptom is emphysema, a chronic condition caused by damage to the air sacs in the lungs that leads to coughing, difficulty breathing, and limits physical activity. A smaller proportion of affected patients also develop liver disease as children or as adults, leading to jaundice and sometimes liver failure.

Clinical Information

Physical Impairment	
Cognitive Impairment	
Shortened Lifespan	
Effective Treatment	

Treatment

Lung transplantation or liver transplantation may be appropriate for patients with end-stage lung disease or liver disease due to Alpha-1-Antitrypsin Deficiency. In general, patients should avoid smoking. Vitamin E therapy has been demonstrated to improve liver function in symptomatic infants and may help prevent oxidative damage to the lungs.

Prognosis

Prognosis is generally favorable. Non-smokers often have a normal life span. Smoking, however, greatly accelerates the disease, particularly as it affects the lungs. Onset of lung disease typically occurs in adulthood. Liver disease presents in only 2% of affected children. Liver disease, however, affects about 19% of adults who live past 50 with this disease.


Carrier Map™

Moderate Impact

Status

Donor 2773: Carrier (1 abnormal copy) Mutation: c.G1096A (p.E366K) Gene: SERPINA1 Method: Genotyping

Inheritance



Carrier Risk Assessment

Ethnicity	Detection Rate	Pre-Test Risk	Post-Test Risk
European	95.00%	1/35	1/700
General	95.00%	Unknown	Unknown





To learn more visit http://recombine.com/diseases/alpha-1-antitrypsin-deficiency



Carrier Map™

Methods and Limitations

Genotyping: Genotyping is performed using the Illumina Infinium Custom HD Genotyping assay to identify mutations in >200 genes. The assay is not validated for homozygous mutations, and it is possible that individuals affected with disease may not be accurately genotyped.

Limitations: In some cases, genetic variations other than that which is being assayed may interfere with mutation detection, resulting in false-negative or false-positive results. Additional sources of error include, but are not limited to: sample contamination, sample mix-up, bone marrow transplantation, blood transfusions, and technical errors.

The test does not test for all forms of genetic disease, birth defects, and intellectual disability. All results should be interpreted in the context of family history; additional evaluation may be indicated based on a history of these conditions. Additional testing may be necessary to determine mutation phase in individuals identified to carry more than one mutation in the same gene. All mutations included within the genes assayed may not be detected, and additional testing may be appropriate for some individuals.



CarrierMap™

Diseases & Mutations Assayed

🛑 High Impact 🔵 Treatment Benefits 🌘 X-Linked 😑 Moderate Impact

нтхм			Mutations
000	Alpha-1-Antitrypsin Deficiency	4	♂ Genotyping c.226_228delTTC (p.76delF), c.A1131T (p.L377F), c.C187T (p.R63C), c.G1096A (p.E366K)

.

X LGN	10 ATTN: SEN 1900 SULL BALTIMORE	RUR SPRING ROAD , MD 21227	/ Nichols in	stitute" Director:	ERVICES - (805) 553-544 Jon Nakamoto, M.D., Pn. 1	d. The
HERE	`		ATENI DNO.		JAIE	
	IENT NAME				04/24/2014	06:35
27	73, DONOR	SEX SAMPLE ID NO.	UTHER ID THU.	RECEIVED	04/28/2014	04:03
		MALE NOT GIVEN	BEPERAND PHYSICIAN	REPORTED	05/06/2014	11:06
REVIAR	iks.			3~\1U3	DUPLICATE	
		APSULT (1 UNITS		NCE RANGE	
/ TES	a Cyp21A2	1,2077.	SEE BELOW	NE	GATIVE	
	Mutation(s) G Allele 1:	V281L	ATION(S) OF CIF	ŪĈĦ ' MŪTĀTĪC	dns .	gene,
	unariected of 21-hydroxyla offered to m by, or carri additional s mutations ma Laboratory x Michael Jary	None DN: DNA testing ind arrier of CAH but 4 se deficiency or C embers of this ind bers of, CAH. If cl tudies such as comy y be indicated. esults and submitt is, Ph.D., ABMG, C	AN disease. This ividual's family inical suspicion plate sequencing ed clinical info GMB.	who are at for diseas of the CYP rmation rev	risk tö be a e remains, 21A2 gene fo iewed by	
و و المحمد الم	About 90% of detected in analysis of 21-hydroxyle genes. Mutat cluster 1236 the pattern svents betwe detection. heterozygou have a dete- with CAH sh since genet	drenal Hyperplasia cessive disorder c both parental cop mutant chromosome this assay. The mu four different PCR ions tested includ ions tested includ ions tested includ ions tested can be u sen CYF2LA2 and its one would expect the a carriers of CAH. ctable mutation on ould not have a de ic variation and o tection, test resu d family data.	is carry one of a products that e orgene, and vario le p30L, Intron 2 (, V28LL, F306+Lr ised to deduce de s pseudogene. Giv ist no mutations Similarly, 18% a single parents tectable mutation ther problems can its should alway	orted by a m liow inspec- ous recombine "g", Gilod ht, O318X, F sletions plu- ren 90% sens would be i of those af al chromusou n on either n affect the s be interp	tini-sequenci tion of the hant forms of RelBut, 1172N 3356W, and Pé us recombinat sitivity for dentified in fected by CAN me and 1% of parantal chi e accuracy o roted in lig	ng those (, Exon 6 1538 and tion mutation 10% of those romosome. t direct ht of
	CYP21A2 gen be required individual preparation interpret e	d family data. otypes can be comp to fully understa chromosome. Family for prenatal diag ither individual o	lex and analysis nd the haplotype studies should nosis and geneti r family results	or pattern always be c c counselin	of markers completed in ig may be use with Rochs MG	on an ful to Jacular
	This test i Systems, In	s performed pursue c. and Orchid Bios	nt to a license ciences Inc.	adraemen.	Line hove had	an
-	This test a determined Performance	vas developed and i by Quest Diagnost a characteristics i	te performance d los Nichols Inst cefer to the ana.	inaracteris Lute, San Lytical per:	Juan Capistra formance of t	ano. the test.
			FR	TERE MONTONIA PATENT NAME		